PDS Biotechnology Corporation — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Financial statements are unaudited. PDS is a clinical-stage immunotherapy company with no approved products and no commercial product revenue; it is developing cancer and infectious-disease candidates using its Versamune, Versamune plus PDS0301, and Infectimune platforms.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development | $8.0 million | $3.8 million | $13.8 million | $8.9 million |
| General and administrative | $4.7 million | $3.3 million | $8.3 million | $6.6 million |
| Total operating expenses | $12.7 million | $7.1 million | $22.1 million | $15.6 million |
| Net loss | $11.5 million | $5.8 million | $21.2 million | $14.3 million |
| Basic and diluted loss per share | $0.37 | $0.20 | $0.69 | $0.50 |
Operating margins are not meaningful because the company reported no revenue. Q2 net loss includes a $1.4 million income tax benefit, associated with New Jersey tax-benefit sales; interest expense also increased following the venture loan.
- Cash and cash equivalents: $60.6 million at June 30, 2023, down from $73.8 million at December 31, 2022.
- Cash flow: $18.0 million used in operating activities during the first half, versus $12.3 million in the prior-year period. Financing provided $4.8 million, primarily from at-the-market stock sales. Cash declined by $13.2 million.
- Balance sheet: Total assets were $63.8 million; total liabilities $31.3 million; stockholders’ equity $32.4 million. Accumulated deficit was $122.8 million.
- Debt: Note payable, net of debt discount, was $23.3 million. The loan bears floating interest at prime plus 5.75% (subject to a 4% minimum), with monthly interest payments; principal amortization is scheduled to begin October 2024. The loan is secured by company assets, excluding intellectual property, and includes financial and operating restrictions.
Changes versus prior comparable periods
- Q2 operating expenses rose 79% year over year, and net loss nearly doubled. For the first half, operating expenses rose 42% and net loss increased by $6.9 million.
- Management attributed higher R&D costs mainly to clinical trials, manufacturing, and personnel. Higher G&A reflected personnel, stock-based compensation, and professional fees.
- Interest income increased, but loan interest expense more than offset it. First-half interest expense was $2.0 million; there was no reported interest expense in the first half of 2022.
- First-half operating cash use increased by $5.7 million year over year. Stock-based compensation was $4.2 million, versus $2.5 million in the prior-year period.
Outlook, developments, and risks
- Management said cash on hand was expected to fund operations and R&D for 12 months following the filing. The company expects continuing losses and anticipates R&D spending will increase as trials advance. It expects to need additional capital; equity financing may dilute shareholders, while debt may add service costs and restrictive covenants.
- Management planned to initiate a Phase 3 trial of PDS0101 with pembrolizumab in Q4 2023, following completion of enrollment in the VERSATILE-002 ICI-naive arm and submission of an amended IND. These are forward-looking plans, not reported outcomes.
- The company reported interim VERSATILE-002 results, including a 41.2% confirmed and unconfirmed response rate among 34 patients in the ICI-naive cohort and a 10.4-month median progression-free survival. The filing notes these results are from a clinical study and are not a controlled comparison with approved therapies.
- The January 2023 exclusive PDS0301 license from Merck KGaA carries up to $11 million in development and first-commercial-sale milestones, up to $105 million in sales milestones, and a 10% royalty on specified net sales, subject to stated terms and potential reductions.
- Two additional $5 million loan tranches were uncommitted and required lender agreement and satisfaction of conditions. The stated option period was through July 31, 2023; the parties were discussing an extension, with no assurance it would be extended.
- Key risks include clinical and regulatory uncertainty, ability to raise capital, potential delays or reductions in development programs, competition, and intellectual-property risks. The company reported no material pending legal proceedings and no material changes to previously disclosed risk factors.
- The filing reports no material non-cancelable purchase commitments, no off-balance-sheet arrangements, and effective disclosure controls and procedures.
Investor verification points
- Verify cash runway assumptions, expected trial spending, and whether additional financing is needed on terms acceptable to shareholders.
- Track the timing and regulatory status of the planned PDS0101 Phase 3 trial and assess the maturity, size, and limitations of reported clinical data.
- Confirm the availability and terms of any extension or funding of the uncommitted loan tranches, and monitor the variable-rate debt and covenant obligations.
- Reconcile the filing’s inconsistent first-half ATM share-sale figures: the financial-statement note reports 596,462 shares, while MD&A reports 576,462; both cite approximately $4.8 million in net proceeds.
- Review the PDS0301 license milestones, royalties, and future cash implications as development progresses.